EMA Clarifies GMP Responsibilities Of Marketing Authorization Holders
The European Medicines Agency says a draft reflection paper is designed to clear up confusion on the responsibilities of marketing authorization holders in ensuring compliance with good manufacturing practices.
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.